Page last updated: 2024-09-05

sorafenib and Carcinogenesis

sorafenib has been researched along with Carcinogenesis in 31 studies

Research

Studies (31)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	14 (45.16)	24.3611
2020's	17 (54.84)	2.80

Authors

Authors	Studies
Chang, JC; Chen, D; Chen, MM; Chen, X; Deng, Y; Gan, B; Hang, Q; Liang, H; Liu, X; Ma, L; Martinez, C; Mei, Y; Rosato, RR; Su, X; Sun, Y; Teng, H; Wang, Y; Xie, D; Yao, F; Yap, S; You, MJ; Zhang, M; Zhang, Y; Zhao, Y; Zhu, H	1
He, Y; Huang, L; Li, H; Li, Q; Liang, S; Lu, W; Luo, Y; Wang, X; Xiong, L; Zhang, D; Zhang, P	1
Chen, J; Chen, T; Cui, Y; Ge, C; Geng, Q; Jin, W; Li, H; Li, J; Lin, H; Liu, T; Miao, C; Tian, H; Xiao, X; Xie, H; Yao, M; Yu, J; Zhao, F; Zhou, Q	1
Kajitani, T; Katakura, S; Maruyama, T; Masuda, H; Miki, F; Miyazaki, K; Takao, T; Tanaka, M; Tomisato, S; Uchida, H; Uchida, S; Yoshimasa, Y	1
Arrese, M; Debes, JD; Manica, M; Mattos, AA; Mattos, ÂZ; Pase, THS; Revelo, X; Vogel, A	1
Chen, MY; Cherng, YG; Fong, IH; Huang, TY; Yadav, VK; Yang, CK; Yeh, CT	1
Chen, B; Li, Q; Liu, B; Luo, M; Miao, J; Song, G; Zeng, K	1
Dong, H; Jing, W; Jun, X; Min, M; Runpeng, Z; Shuo, L; Yingru, X	1
Li, H; Li, X; Liu, J; Ma, Y; Peng, X; Yang, L; Yang, S; Zhou, Y	1
Ding, G; Dong, J; Fu, Z; Guo, W; Liu, F; Liu, H; Mao, J; Sha, Z; Song, S; Sun, K; Zhao, Y	1
Alseth, I; Aukrust, P; Berges, N; Bjørås, M; Dahl, TB; Fladeby, C; Gregersen, I; Halvorsen, B; Holm, S; Klungland, A; Kong, XY; Nawaz, MS; Quiles-Jiménez, A; Segers, F; Suganthan, R; Vågbø, C; Vik, ES	1
Manoharan, R; Natarajan, SR; Ponnusamy, L; Thangaraj, K	1
Feng, JQ; Fu, ZQ; Li, D; Li, H; Luo, H; Peng, JJ; Sun, FF; Wang, C; Wang, D; Wang, T; Zhang, T; Zhou, DJ	1
Cheng, AS; Feng, H; Gao, Y; Huang, L; Jiang, Y; Le, F; Li, M; Sun, X; Yu, DY; Yu, Z; Zhang, X; Zheng, C; Zhou, Z; Zhu, X; Zhuo, Y	1
Chan, AC; Chan, LK; Cheung, ET; Cheung, TT; Chiu, EY; Chok, KS; Ho, DW; Kam, CS; Lee, TK; Lo, IL; Ng, IO; Tang, CN; Tang, VW; Wong, CC; Wong, CM; Yau, DT	1
Li, D; Li, W; Liu, M; Yang, D; Zhang, Y; Zhao, S	1
Ebrahim, S; Hashemi, S; Moosavi, MA; Motamedi, M; Rahmati, M	1
Abdouni, A; Allende, DS; Apte, SS; Arechederra, M; Audebert, S; Bazai, SK; Daian, F; Dono, R; Gregoire, D; Hibner, U; Lozano, A; Maina, F; Mead, TJ; Richelme, S; Sequera, C	1
Chen, B; Dai, HT; Huang, YH; Li, N; Lin, R; Liu, N; Tang, KY; Yang, JY	1
Antoniewicz, MR; Au, J; DeWaal, D; Guzman, G; Hay, N; Jeon, SM; Long, CP; Nogueira, V; Patra, KC; Terry, AR	1
Du, J; Zhou, XJ	1
Huang, W; Huang, XY; Ke, AW; Liu, D; Wang, F; Wu, J; Wu, Y; Zhang, PF; Zhang, XM	1
Chai, CY; Chiang, CM; Chiou, SS; Hsu, SH; Huang, SK; Liu, KY; Wang, LT; Wang, SN; Yokoyama, KK	1
Lin, B; Nie, J; Wu, L; Zheng, T; Zhou, M	1
Chen, GY; Cheng, Y; Huang, C; Li, AW; Su, J; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhou, CC; Zhou, Q	1
Jiang, X; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O	1
Chen, S; Dong, L; Fang, Y; Hu, T; Huang, X; Ji, L; Liu, T; Shen, X; Tang, W; Wang, Y; Weng, S; Wu, J; Xue, R; Zhang, S	1
Delire, B; Stärkel, P	1
George, J; Hebbard, L; Qiao, L; Wilson, G; Wu, G; Zhou, G	1
Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T	1
He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y	1

Reviews

6 review(s) available for sorafenib and Carcinogenesis

Article	Year
Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? World journal of gastroenterology, 2022, Jul-28, Volume: 28, Issue:28 Topics: Bevacizumab; Carcinogenesis; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Sorafenib	2022
Therapeutic aspects of AMPK in breast cancer: Progress, challenges, and future directions. Biochimica et biophysica acta. Reviews on cancer, 2020, Volume: 1874, Issue:1 Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Aspirin; Biological Products; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Enzyme Activators; Female; Humans; Metformin; Phosphorylation; Signal Transduction; Sorafenib; Treatment Outcome	2020
New insights on the role of autophagy in the pathogenesis and treatment of melanoma. Molecular biology reports, 2020, Volume: 47, Issue:11 Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Carcinogenesis; Gene Expression; Humans; Melanoma; Skin Neoplasms; Sorafenib	2020
Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers. Critical reviews in oncogenesis, 2017, Volume: 22, Issue:5-6 Topics: Biomarkers, Tumor; Carcinogenesis; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Prognosis; Sorafenib; Sunitinib; Thymus Neoplasms	2017
Role of ferroptosis in hepatocellular carcinoma. Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:12 Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Death; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Lipid Metabolism; Liver Neoplasms; Signal Transduction; Sorafenib	2018
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. European journal of clinical investigation, 2015, Volume: 45, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinogenesis; Carcinoma, Hepatocellular; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Monomeric GTP-Binding Proteins; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; ras GTPase-Activating Proteins; ras Proteins; Rats; Sorafenib; Tumor Suppressor Proteins	2015

Trials

1 trial(s) available for sorafenib and Carcinogenesis

Article	Year
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). Lung cancer (Amsterdam, Netherlands), 2014, Volume: 83, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinogenesis; China; ErbB Receptors; Female; Genotype; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Sequence Deletion; Sorafenib; Survival Analysis; Treatment Failure	2014

Article

Year

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).

Lung cancer (Amsterdam, Netherlands), 2014, Volume: 83, Issue:3

Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinogenesis; China; ErbB Receptors; Female; Genotype; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Sequence Deletion; Sorafenib; Survival Analysis; Treatment Failure

2014

Other Studies

24 other study(ies) available for sorafenib and Carcinogenesis

Article	Year
A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nature communications, 2021, 12-17, Volume: 12, Issue:1 Topics: Animals; Antibodies, Neutralizing; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Ferroptosis; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Leukemia Inhibitory Factor Receptor alpha Subunit; Lipocalin-2; Liver Neoplasms; Male; Mice, Inbred C57BL; NF-kappa B; Piperazines; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; Up-Regulation; Xenograft Model Antitumor Assays	2021
PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. Cell death & disease, 2022, 02-04, Volume: 13, Issue:2 Topics: Animals; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Glycolysis; Humans; Kidney Neoplasms; Mice; Phosphoglycerate Kinase; Receptors, CXCR4; Signal Transduction; Sorafenib	2022
Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma. Cancer letters, 2022, 06-28, Volume: 536 Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lamin Type A; Lipogenesis; Liver Neoplasms; Mice; Orlistat; Sorafenib; Sterol Regulatory Element Binding Protein 1	2022
Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway. Stem cell research & therapy, 2022, 06-03, Volume: 13, Issue:1 Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Humans; Ki-67 Antigen; MAP Kinase Signaling System; Mice; Neoplastic Stem Cells; Sorafenib	2022
Furanocoumarin Notopterol: Inhibition of Hepatocellular Carcinogenesis through Suppression of Cancer Stemness Signaling and Induction of Oxidative Stress-Associated Cell Death. Nutrients, 2023, May-24, Volume: 15, Issue:11 Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum Stress; Furocoumarins; Humans; Liver Neoplasms; Mice; Oxidative Stress; Sorafenib	2023
CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances sorafenib sensitivity via the ROS/PPARγ/NF-κB pathway in clear cell renal cell carcinoma. Cellular signalling, 2023, Volume: 110 Topics: Carcinogenesis; Carcinoma; Carcinoma, Renal Cell; Carnitine O-Palmitoyltransferase; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Fatty Acids; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; NF-kappa B; PPAR gamma; Reactive Oxygen Species; Sorafenib	2023
Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma. Biochemical and biophysical research communications, 2019, 10-29, Volume: 519, Issue:1 Topics: Animals; Apoptosis; Artesunate; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Liver Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Sorafenib; TOR Serine-Threonine Kinases	2019
LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma. Journal of cellular physiology, 2020, Volume: 235, Issue:4 Topics: Autophagy; Autophagy-Related Proteins; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; RNA, Long Noncoding; Sorafenib; Ubiquitin-Conjugating Enzymes	2020
microRNA-29a regulates liver tumor-initiating cells expansion via Bcl-2 pathway. Experimental cell research, 2020, 02-15, Volume: 387, Issue:2 Topics: 3' Untranslated Regions; Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Self Renewal; Down-Regulation; Hep G2 Cells; Heterografts; Humans; Liver; Liver Neoplasms; Mice; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib	2020
Deletion of Endonuclease V suppresses chemically induced hepatocellular carcinoma. Nucleic acids research, 2020, 05-07, Volume: 48, Issue:8 Topics: Adenosine; Animals; Antineoplastic Agents; Carcinogenesis; Cell Line; Deoxyribonuclease (Pyrimidine Dimer); Gene Expression; Humans; Inosine; Liver; Liver Neoplasms, Experimental; Mice, Knockout; RNA Editing; RNA, Transfer; Sequence Analysis, RNA; Sorafenib	2020
Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells. Oncology research, 2020, 12-10, Volume: 28, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; NF-E2-Related Factor 2; RNA, Small Interfering; Sorafenib	2020
Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation. Cellular oncology (Dordrecht), 2020, Volume: 43, Issue:6 Topics: Animals; beta Catenin; Bufanolides; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Glycogen Synthase Kinase 3 beta; Hepatitis B virus; Liver Neoplasms; Mice, Nude; Mice, Transgenic; Models, Biological; Phosphorylation; Proteolysis; Receptors, Androgen; Signal Transduction; Sorafenib; Trans-Activators; Viral Regulatory and Accessory Proteins	2020
RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. Journal of hepatology, 2021, Volume: 74, Issue:2 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; Exome Sequencing; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Loss of Function Mutation; MAP Kinase Signaling System; Ribosomal Protein S6 Kinases, 90-kDa; Sorafenib	2021
Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression. Oncology reports, 2020, Volume: 44, Issue:5 Topics: Adult; Aged; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Nephrectomy; Receptors, CXCR5; RNA, Long Noncoding; Sorafenib; Xenograft Model Antitumor Assays	2020
ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. Journal of hepatology, 2021, Volume: 74, Issue:4 Topics: ADAMTS Proteins; ADAMTS5 Protein; Animals; Antineoplastic Agents, Immunological; Benzocycloheptenes; Carcinogenesis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epigenomics; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Phenylurea Compounds; Quinolines; Signal Transduction; Sorafenib; Transcriptional Activation; Triazoles; Tumor Microenvironment	2021
The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats. Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Drug Administration Schedule; Heterografts; Immunohistochemistry; Liver Neoplasms, Experimental; Mice, Inbred BALB C; Mice, Nude; Microvessels; Rats; Rats, Sprague-Dawley; Sorafenib; Survival Analysis; Time Factors; Up-Regulation; Vascular Endothelial Growth Factor A	2018
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nature communications, 2018, 01-31, Volume: 9, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Glycolysis; Hep G2 Cells; Hexokinase; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Metabolic Flux Analysis; Metformin; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays	2018
LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma. Journal of cellular physiology, 2019, Volume: 234, Issue:3 Topics: Carcinogenesis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; RNA, Long Noncoding; Sorafenib; Tetraspanin 24	2019
TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer. Oncogene, 2019, Volume: 38, Issue:4 Topics: Acetylation; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lysine Acetyltransferase 5; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Nuclear Proteins; Protein Interaction Mapping; Protein Processing, Post-Translational; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transcription Factors; Twist-Related Protein 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2019
Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. Experimental cell research, 2014, May-01, Volume: 323, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cells, Cultured; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Hep G2 Cells; Hepatocytes; Humans; Niacinamide; Phenylurea Compounds; Receptors, Androgen; RNA, Messenger; Sorafenib	2014
BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation. International journal of cancer, 2015, Mar-15, Volume: 136, Issue:6 Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tumor Suppressor Protein p53; Ubiquitination	2015
Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma. Discovery medicine, 2015, Volume: 20, Issue:110 Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Green Fluorescent Proteins; Humans; Liver Neoplasms; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Octamer Transcription Factor-3; Phenylurea Compounds; Sorafenib; Spheroids, Cellular	2015
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. BMC cancer, 2016, Jan-19, Volume: 16 Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib; Thyroid Neoplasms	2016
Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 88 Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Humans; Interferons; Interleukins; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice, Nude; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib	2017